InvestorsHub Logo
Followers 35
Posts 1202
Boards Moderated 1
Alias Born 08/27/2000

Re: vinmantoo post# 305536

Wednesday, 07/26/2017 10:50:47 AM

Wednesday, July 26, 2017 10:50:47 AM

Post# of 345853
This is called, "endogenous protein cross reactivity".

In other words a lot of biologic competition for a clumsy therapeutic, IMO.

They could theoretically eliminate some competition by introducing specific statin combination that would reduce b2gp1 antigen presentation (from domain V2 epitope) to LDL receptor. Just saying..

Also, if ever a molecule needed exact PK data, this would be it.

All the best,
John

Disclaimer: Every post, and all my views are only speculative. Do not invest money or any other resources based on these post or opinions. Best of luck and do your own due diligence!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News